Drug Profile


Alternative Names: AR 336; LY 122772; Zinviroxime

Latest Information Update: 12 Jan 2004

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antivirals; Benzimidazoles; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • No development reported Coxsackievirus infections; Picornavirus infections

Most Recent Events

  • 12 Jan 2004 No development reported - Preclinical for Coxsackievirus infections in Bulgaria (unspecified route)
  • 14 Aug 2001 No-Development-Reported for Picornavirus infections in USA (Unknown route)
  • 09 May 2001 A preclinical study has been added to the Viral Infections pharmacodynamics and antimicrobial activity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top